Noxopharm Ltd. (NOX) AI Stock Analysis

• Market Cap: AU$19.00M
• Dividend Yield: N/A
• Average Volume (3M): 111.59K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.04
• Revenue Growth: N/A
• EPS Growth: 80.96%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 55
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 292,237,950
• 10 Day Avg. Volume: 138,508
• 30 Day Avg. Volume: 111,587
• PEG Ratio: 0.04
• Price to Book (P/B): 1.38
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.15
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 36 Underperform
• Price Target: ―

Noxopharm Ltd. faces significant financial difficulties, with declining revenues and negative profitability, heavily weighing down its stock score. Technical analysis shows a neutral to slightly negative trend, while valuation highlights unprofitability challenges. The absence of earnings call data and corporate events means these factors have not influenced the score.

Noxopharm Ltd. Business Overview & Revenue Model

Company Description

Noxopharm Ltd. (NOX) is an Australian-based biotechnology company that focuses on the development of innovative oncology drug candidates. The company's core products are centered around its proprietary drug technology designed to enhance the effectiveness of existing cancer treatments, particularly in enhancing the body's response to radiotherapy and chemotherapy. Noxopharm operates within the pharmaceutical and biotechnology sectors, aiming to address unmet medical needs in cancer treatment through its novel drug formulations.

How the Company Makes Money

Noxopharm Ltd. generates revenue primarily through the development and commercialization of its drug candidates, particularly those targeting cancer treatment. The company earns money by advancing its proprietary drug technology through clinical trials and obtaining regulatory approvals, which can lead to partnerships with larger pharmaceutical companies or direct commercialization. Additionally, Noxopharm may engage in licensing agreements, where it licenses its technology to other companies in exchange for upfront payments, milestone payments, and royalties on future sales. Strategic partnerships and collaborations with research institutions and other biotech companies can also provide funding and support for their drug development programs, contributing to their revenue streams.

Noxopharm Ltd. Financial Statement Overview

Summary

Noxopharm Ltd. is facing substantial financial challenges, characterized by declining revenues, negative profitability, and poor cash flow performance. Despite having no debt and a strong equity ratio, the company struggles to generate shareholder value and maintain operational efficiency. The firm needs to focus on improving its revenue trajectory and cost management to enhance its financial health.

Income Statement

Noxopharm Ltd. has experienced a significant decline in revenue over the past year, with a revenue decrease of approximately 60% from 2023 to 2024. The company also reports negative gross profit and net income, indicating struggles in profitability. The negative EBIT and EBITDA margins highlight considerable operational inefficiencies, suggesting that the firm is facing challenges in managing its cost structure.

Balance Sheet

The balance sheet displays a positive equity position, with no debt, which suggests a conservative capital structure. However, the return on equity is negative due to consistent net losses, reflecting poor shareholder value generation. The equity ratio remains strong, indicating that the company is primarily financed through equity.

Cash Flow

Noxopharm Ltd. is facing negative free cash flow, although there is an improvement in cash outflows compared to the previous year, indicating some progress in managing cash. The operating cash flow to net income ratio reflects challenges in converting profits into cash, while the absence of capital expenditures suggests limited investment in growth.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
2.34M	2.40M	6.01M	5.43M	5.61M	8.28M
	Gross Profit
-690.28K	-534.81K	5.86M	5.17M	5.35M	8.04M
	EBIT
-7.64M	-7.54M	-16.60M	-15.21M	-14.61M	-16.37M
	EBITDA
-4.60M	-5.95M	-20.85M	-23.70M	-5.85M	-4.53M
	Net Income Common Stockholders
-2.32M	-3.58M	-15.06M	-18.67M	-9.35M	-272.09K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.18M	2.32M	3.01M	14.01M	26.80M	7.10M
	Total Assets
5.47M	6.78M	10.13M	26.59M	47.85M	20.07M
	Total Debt
0.00	0.00	0.00	160.62K	349.31K	5.00M
	Net Debt
-1.04M	-2.32M	-3.01M	-13.85M	-26.45M	-2.10M
	Total Liabilities
1.14M	1.29M	1.06M	2.48M	7.08M	7.19M
	Stockholders Equity
4.32M	5.50M	9.07M	24.12M	40.78M	12.87M
Cash Flow		Free Cash Flow
-4.08M	-684.31K	-10.95M	-13.73M	-8.85M	-11.14M
	Operating Cash Flow
-4.08M	-684.31K	-10.95M	-13.73M	-8.85M	-11.14M
	Investing Cash Flow
0.00	0.00	123.51K	0.00	225.23K	337.81K
	Financing Cash Flow
0.00	0.00	-178.09K	975.73K	28.32M	14.99M

Noxopharm Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NOX, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and below the 200-day MA of 0.09, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 27.83 is Positive, neither overbought nor oversold. The STOCH value of -64.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NOX.

Noxopharm Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RAC	54 Neutral	AU$196.32M	―	-37.20%	―	―	32.02%
Sector *	54 Neutral	$5.34B	3.27	-45.10%	3.30%	16.80%	0.02%
PYC	53 Neutral	AU$676.58M	―	-112.97%	―	―	-84.82%
PIQ	44 Neutral	AU$60.50M	―	-131.55%	―	12.53%	-11.04%
NOX	36 Underperform	AU$19.00M	―	-42.50%	―	―	80.96%
BIT	36 Underperform	AU$2.65M	―	-119.28%	―	―	64.10%
OPT	30 Underperform	$738.77M	―		―	-24.46%	-7.90%

Noxopharm Ltd. Corporate Events

Noxopharm Advances SOF-SKN™ to First Human Trials in Australia

Noxopharm Limited has submitted an application to the Human Research Ethics Committee for approval to conduct the HERACLES clinical trial, following successful preclinical testing. This trial marks the first-in-human study for SOF-SKN™, a novel drug candidate aimed at treating autoimmune diseases, specifically targeting cutaneous lupus erythematosus as a proof of concept. Conducting the trial in Australia allows Noxopharm to benefit from local expertise and federal R&D tax incentives, potentially positioning the company as a leader in autoimmune disease treatment. The success of this trial could pave the way for further development of the Sofra technology for other immune-related conditions.

Noxopharm Advances Drug Development with Key Agreements and Preclinical Success

Noxopharm Limited has announced significant progress in its quarterly activities, including a follow-on Material Transfer Agreement with an international company, highlighting growing interest in its Sofra technology platform. The company also reported that its novel drug candidate, SOF-SKN™, successfully passed preclinical tests, paving the way for a clinical trial aimed at treating autoimmune diseases like lupus. These developments position Noxopharm to capitalize on the expanding global RNA market and strengthen its industry standing.

Noxopharm’s Lupus Drug Clears Final Preclinical Hurdle

Noxopharm Limited announced that its lupus medication, SOF-SKN™, has successfully passed the final in vivo preclinical safety study, paving the way for submission to the Human Research Ethics Committee for the HERACLES clinical trial. This milestone marks a significant step towards exploring the drug’s potential in treating autoimmune diseases, with the company aiming to expand into larger markets such as rheumatoid arthritis and other inflammatory diseases. The global autoimmune disease market is projected to grow significantly, highlighting the potential impact of Noxopharm’s advancements on the industry and stakeholders.

Noxopharm Expands Strategic Collaboration to Advance Sofra™ Platform

Noxopharm Limited has announced an expansion of its collaboration with the Hudson Institute of Medical Research, aiming to advance its Sofra™ platform. This expansion will focus on exploring new targets in inflammation sensors and advancing cancer research, with the upcoming HERACLES trial marking a significant milestone. The partnership is based on a breakthrough discovery that explains the role of RNA fragments in autoimmune diseases, which underpins the development of new drugs to restore immune system balance. This development positions Noxopharm as a leading player in the growing RNA market, potentially impacting its industry positioning and offering new commercial opportunities.

Noxopharm Partners with Doherty Clinical Trials for HERACLES Trial

Noxopharm Limited has announced a partnership with Doherty Clinical Trials to conduct the HERACLES clinical trial in Melbourne. This collaboration will leverage the expertise of Doherty Clinical Trials, renowned for its experience in early phase studies and immunology, to advance Noxopharm’s innovative SOF-SKN™ drug for lupus. This strategic move is expected to strengthen Noxopharm’s position in the biotech industry by showcasing its commitment to addressing unmet medical needs and enhancing its drug development pipeline.

Noxopharm Reports Half-Year Financial Results and Strategic Focus

Noxopharm Limited reported its financial results for the half-year ending December 2024, highlighting a cash balance of $1.0 million and an investment of $1.6 million in R&D to advance drug discovery. The company is preparing for the HERACLES clinical trial for its lupus drug candidate, SOF-SKN™, and is pursuing Material Transfer Agreements to leverage interest in its Sofra™ technology platform. These efforts reflect Noxopharm’s strategic focus on cost management and advancing its drug development pipeline, which could impact its market positioning and stakeholder interests.